AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NewAmsterdam Pharma Stock Soars 5.25% on Bullish Analyst Ratings
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jun 18, 2025 8:29 am ET1min read
On June 18, 2025, NewAmsterdam Pharma's stock surged by 5.25% in pre-market trading, reflecting a strong bullish sentiment among investors.
Citigroup has initiated coverage on
, assigning it a 'Buy' rating and setting a target price of $42. The firm highlights the significant unmet need in the LDL cholesterol lowering market, where a substantial portion of patients with atherosclerotic cardiovascular disease still require additional therapies to reach their targeted LDL-C levels. NewAmsterdam's obicetrapib is positioned as a first-in-class agent that could be used as an add-on to statins or in combination therapy with ezetimibe for those needing further lipid lowering.Needham & Company LLC has also reissued a 'buy' rating on NewAmsterdam Pharma, setting a price target of $40. This reiteration of a positive outlook underscores the growing confidence in the company's potential within the biotech sector.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Oracle shares surge 6.63% on renewed investor confidence in strategic AI positioning
Dec.22 2025
Broadcom shares surge 3.18% on analyst upgrades and AI infrastructure momentum
Dec.22 2025
Nvidia Corp shares surge 3.93% on AI sector developments and cloud partnership rumors
Dec.22 2025
Bit Digital (BTBT) surges 10.40% after S&P Software & Services Select Industry Index inclusion
Dec.22 2025
New Found Gold (TSXV:NFG) Surges 5.73% on Construction Completion and $30M Financing
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet